(Q34584163)

3 August 2017

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study (English)

1 reference

3 August 2017

0 references

7

Robert J Motzer

1 reference

3 August 2017

4

George Wilding

1 reference

3 August 2017

1

Olivier Rixe

1 reference

3 August 2017

Ronald M Bukowski

2

1 reference

3 August 2017

M Dror Michaelson

3

1 reference

3 August 2017

Gary R Hudes

5

1 reference

3 August 2017

Oliver Bolte

6

1 reference

3 August 2017

Paul Bycott

8

1 reference

3 August 2017

Katherine F Liau

9

1 reference

3 August 2017

James Freddo

10

1 reference

3 August 2017

Peter C Trask

11

1 reference

3 August 2017

Sinil Kim

12

1 reference

3 August 2017

Brian I Rini

13

1 reference

3 August 2017

23 October 2007

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

8

1 reference

3 August 2017

975-984

1 reference

3 August 2017

11

1 reference

3 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970285-1

7 January 2021

10.1016/S1470-2045(07)70285-1

Identifiers

DOI

1 reference

3 August 2017

1 reference